Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration.

Publisher Website
Google Scholar
Abstract
Because of biochemical and tissue culture evidence casting doubt on the physiologic relevance of reported synergy afforded by sequential administration of methotrexate (MTX) followed by 5-fluorouracil (5-FU), a randomized controlled clinical trial was conducted in 108 patients with advanced cancer, including 70 with squamous cell carcinoma (SCC) of the head and neck, 9 with SCC of other primary sites, 24 with colorectal and 5 with gastric adenocarcinomas. Patients were randomized to receive weekly therapy consisting of MTX followed 1 h later by 5-FU, or 5-FU followed 1 h later by MTX. There was a trend to higher tumor response rates in patients treated with MTX before 5-FU (45 vs. 33% overall; 65 vs. 39% in patients with previously untreated head and neck cancer), but these differences were not significant, either by chi-square test or by multivariate stepwise logistic regression. The trend in survival favoring the reverse sequence of 5-FU before MTX was not significant in univariate analyses. Stepwise multivariate Cox model analysis showed that Eastern Cooperative Oncology Group performance status at study entry was the major prognostic factor for survival (P < 0.001), but among the 7.0 patients with head and neck cancer, the sequence of drug administration was the only other significant prognostic factor for survival and favored the sequence of 5-FU followed by MTX (P < 0.025).